/
Baird Medical Investment Holdings Limited is a medical devices company specializing in microwave ablation technology for minimally invasive tumor treatment. The company develops and manufactures microwave ablation apparatus, needles, and related medical devices used to treat benign and malignant tumors, including thyroid nodules, liver cancer, lung cancer, breast lumps, and bone lesions. Operating primarily in the People's Republic of China, Baird Medical positions its microwave ablation systems as safer alternatives to traditional surgical approaches, offering patients faster recovery times and lower complication rates. The company's products are FDA 510(k)-certified and have been deployed across hospitals and clinics internationally. Baird Medical distributes its microwave ablation devices and consumables through third-party distributors and maintains a focus on expanding its presence in minimally invasive medical interventions. The company also pursues research and development initiatives in surgical robotics and intelligent diagnostic systems to complement its core medical device business.
$1.06
+$0.01 (+0.95%)
EOD Jul 17, 2026
The business is unprofitable at the operating level (-113.31% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 39.2% YoY. Margins deteriorated 154.7pp alongside, both lines moving the wrong way.
ROIC dropped from 25.40% to -36.30%, capital efficiency is deteriorating. Negative free cash flow of -$1M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$23M
▼ -39.2% YoY
Net Income (TTM)
-$28M
▼ -318.6% YoY
Op. Margin
-113.31%
▼ -154.7pp YoY
ROIC
-36.30%
▼ -61.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$1M
▲ +84.9% YoY
Op. Cash Flow (TTM)
-$1M
▲ +59.4% YoY
Net Debt
$19M
Cash & Equiv.
$178K
3Y CAGR: -13.7%
Continue Research
Baird Medical Investment Holdings (BDMD)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Baird Medical Investment Holdings scores 10/100 on Intrinsiqq's quality scorecard, weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Baird Medical Investment Holdings scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -113.3% operating margin and a -36.3% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh BDMD's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.